The market will react to the clinical trial updates and finally value the MC accordingly and totally disregard the crap management, target MC of $1.5B with commencement of registrational clinical trial for Azer-Cel and excellent clinical trial updates from OASIS and further positive clinical trial update for VAXINIA. A lot were negative on the poster presentation for CCA with the data from 4 months ago but they look further positive with CF33 working as expected which LC and YF has been telling the market, no additional CR yet but 2 patients showing pseudo progression with very strong reaction to CF33.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)